Common use of Defined Term Section Clause in Contracts

Defined Term Section. JDC Proposal Notice 5.1 Joint Commercialization Committee 2.3 Joint Development Committee 2.2 Joint Inventions 10.1.2(a) Joint Know-How 10.1.1 Joint Manufacturing Subcommittee 7.5 Key Milestone 3.5 Label Expansion 5.1 Liabilities 13.1 Liabilities for an Intrinsic Defect 13.4 Loan 6.4.1(b) Milestone 6.2.3 NDA Initiation 8.1.1 Negotiating Party 2.2.1(l) New Compound License 5.4 New Compound Negotiation Period 5.4 Non-VCM Improvements 9.5.2 Notice Date 15.5.3(a)(i) Notice Period 15.5.3(a)(i) Other Formulation 5.1 Otsuka Introduction Otsuka Indemnitees 13.1 Otsuka Inventions 10.1.2(a) Parties Introduction Party Introduction Patent Infringement Claim 10.3.2 Patent Prosecution Plan 2.2.1(o) Paying Party 6.3.6 Permitted Overrun 6.6 Pharmacovigilance Agreement 8.4 Phase II Costs 6.4.1(a) Phase III Costs 6.4.1(a) Preexisting Product 2.1.2 * Confidential Treatment Requested. Execution Copy Defined Term Section Product Infringement Claim 10.4 Product Recall Expenses 8.5 Product Withdrawal Expenses 8.6 Promissory Note 6.4.1(b) Providing Party 9.7.3 Receiving Party 9.7.3 Research Cost 5.5.4(a) Research Plan 5.5.1 Research Program Term 5.5.4(a) Responding Party 6.9.2 Royalty for Shared Territory 6.3.2 Royalty for Sole Territory 6.3.1

Defined Term Section. JDC Proposal Added Patent(s) 2.1.3(a) Additional Shares Issuance 4.2.2 Adjustment Equity 4.2.2 Advance Payment 5.2.3 Agreement Preamble Bankruptcy Action 8.3.6 Carve-Out Patent Rights 5.1.2 Combination Product 1.18 Common Stock 4.2.1 CHOP Preamble Effective Date Preamble Fair Market Value 1.26 Financial Report 4.8 Financing Event 4.2.2 Funding Commitment 2.1.4 Fully Diluted 4.2.1 Historic Patent Cost 5.2.1 Independent Subproduct 1.18 Infringement Notice 5.1 Joint Commercialization Committee 2.3 Joint Development Committee 2.2 Joint Inventions 10.1.2(a5.4.1 Inventor(s) Joint Know-How 10.1.1 Joint Manufacturing Subcommittee 7.5 Key Recitals License 2.1.2 Licensee Preamble Maintenance Fee 4.3 Method 1.24 Milestone 3.5 Label Expansion 5.1 Liabilities 13.1 Liabilities for an Intrinsic Defect 13.4 Loan 6.4.1(b) 4.4.1.1 Milestone 6.2.3 NDA Initiation 8.1.1 Negotiating Payment 4.4.1.1 Xxxxxx SRA Recitals Minimum Annual Royalty 4.5.6 Ongoing Patent Costs 5.2.2 Parties Preamble Party 2.2.1(l) New Compound Preamble Patent Costs 5.2.1 Patent Counsel 5.1.1 Patent Termination Notice 5.3 Xxxxx SRA Recitals Penn Preamble Institutions’ Indemnitees 7.1.1 Penn Sublicense Income 4.6 Permitted Assignment 9.6.2 Progress Reports 3.4.1 Prosecution Request 5.1.2 Representative 5.6.3 Research License 5.4 New Compound Negotiation Period 5.4 Non-VCM Improvements 9.5.2 Notice Date 15.5.3(a)(i) Notice Period 15.5.3(a)(i) Other Formulation 5.1 Otsuka Introduction Otsuka Indemnitees 13.1 Otsuka Inventions 10.1.2(a) Parties Introduction Party Introduction Patent Infringement Claim 10.3.2 Patent Prosecution Plan 2.2.1(o) Paying Party 6.3.6 Permitted Overrun 6.6 Pharmacovigilance Agreement 8.4 Phase II Costs 6.4.1(a) Phase III Costs 6.4.1(a) Preexisting Product 2.1.2 * Confidential Treatment Requested. Execution Copy Defined 2.1.1 Royalty 4.5.1 SRA Recitals Subfield 1.9 Sublicense 2.4 Term Section Product Infringement Claim 10.4 Product Recall Expenses 8.5 Product Withdrawal Expenses 8.6 Promissory Note 6.4.1(b) Providing Party 9.7.3 Receiving Party 9.7.3 Research Cost 5.5.4(a) Research Plan 5.5.1 Research Program Term 5.5.4(a) Responding Party 6.9.2 Royalty for Shared Territory 6.3.2 Royalty for Sole Territory 6.3.18.1

Defined Term Section. JDC Proposal Notice 5.1 Joint Commercialization Committee 2.3 Joint Development Committee 2.2 Joint Inventions 10.1.2(aMAA 1.104 Manufacturing Improvement Technology Transfer 5.7(c) Joint KnowManufacturing Technology Transfer 5.7(b) Manufacturing Technology Transfer Costs 5.7(b) Manufacturing Technology Transfer Plan 5.7(b) Materials 4.10 NDA 1.104 Non-How 10.1.1 Joint Compete Period 2.9(a) Ongoing Manufacturing Subcommittee 7.5 Key Contracts 5.7(a) Party/Parties Preamble Patent Certification 8.3(a) PDE Exhibit H PPACA 1.106 Pricing and Reimbursement Approvals 1.40 Product Infringement 8.3(a) Protocol 13.3(d) PHSA 8.3(a) Receiving Party 9.1 Regulatory Audit 4.6(f)(ii) Regulatory Milestone 3.5 Label Expansion 5.1 Liabilities 13.1 Liabilities for an Intrinsic Defect 13.4 Loan 6.4.1(bEvent 6.5 Regulatory Milestone Payment 6.5 Remainder 8.3(f) Milestone 6.2.3 NDA Initiation 8.1.1 Negotiating Representatives 9.1 Research Budget 4.2(b) Research Plan 4.2(a) Research Plan Clinical Activities 4.2(a) Research Plan IND-Enabling Studies 4.2(a) Research Plan Manufacturing Activities 4.2(a) Research Program 4.1 Responsible Party 2.2.1(l8.2(c)(ii) New Compound License 5.4 New Compound Royalty Term 6.8 RSV Negotiation Period 5.4 Non-VCM Improvements 9.5.2 Notice Date 15.5.3(a)(i2.10 Sales Milestone Event 6.6 Sales Milestone Payment 6.6 SEC 9.5(a) Notice Period 15.5.3(a)(iSenior Executive 3.1(f) Other Formulation 5.1 Otsuka Introduction Otsuka Indemnitees 13.1 Otsuka Inventions 10.1.2(aTargeting Domain 1.7(b) Parties Introduction Term 11.1 Termination License 11.7(c)(ii) Third Party Introduction Patent Infringement Claim 10.3.2 Patent Prosecution Plan 2.2.1(oCompetitive Product 8.3(a) Paying Third Party 6.3.6 Permitted Overrun 6.6 Pharmacovigilance Agreement 8.4 Phase II Costs 6.4.1(a) Phase III Costs 6.4.1(a) Preexisting Product 2.1.2 * Confidential Treatment Requested. Execution Copy Licenses 6.10 Defined Term Section Product Infringement Claim 10.4 Product Recall Expenses 8.5 Product Withdrawal Expenses 8.6 Promissory Note 6.4.1(bTransferred IND 5.5(b)(ii) Providing Party 9.7.3 Receiving Party 9.7.3 Research Cost 5.5.4(aUpfront Payment 6.1 Withholding Tax Action 7.3 WuXi 1.146 WuXi [***] Obligations 5.7(d)(ii) Research Plan 5.5.1 Research Program Term 5.5.4(aWuXi Sublicense 5.7(d)(ii) Responding Party 6.9.2 Royalty for Shared Territory 6.3.2 Royalty for Sole Territory 6.3.1WuXi Sublicense Agreement 5.7(d)(iii) WuXi Sublicense Option 5.7(d)(ii)